Inzolfi

Fingolimod, the active ingredient in Inzolfi, is a sphingosine‑1‑phosphate receptor modulator presented as an oral formulation for oral use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients. GNH USA supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inzolfi belongs to the sphingosine‑1‑phosphate receptor modulator class and is used in the management of multiple sclerosis. - Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows accumulation of disability. - Active secondary progressive multiple sclerosis: delays disability progression in patients with active disease. - Clinically isolated syndrome at high risk of conversion: may postpone the onset of definite multiple sclerosis.

Fingolimod may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: occasional loose stools. - Nausea: transient feeling of queasiness. - Fatigue: persistent tiredness. - Upper respiratory tract infection: mild cold‑like symptoms. - Hypertension: modest increase in blood pressure.

Serious or Rare Side Effects: - Infections: opportunistic or severe bacterial, viral, or fungal infections. - Cardiac arrhythmia: bradycardia or atrioventricular block, especially after first dose. - Macular edema: vision‑affecting swelling of the retina. - Hepatic injury: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare, potentially fatal brain infection.

Before initiating therapy, clinicians should evaluate several safety parameters. - Lymphocyte monitoring: check baseline and periodic counts to detect lymphopenia. - Cardiac assessment: perform ECG and monitor heart rate during first dose. - Liver function: obtain baseline transaminases and repeat as needed. - Infection risk: screen for active infections and postpone treatment if present. - Vaccination: avoid live vaccines while on therapy. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Fingolimod can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase fingolimod exposure. - Live attenuated vaccines: risk of vaccine‑derived infection. - Drugs that prolong QT interval: additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels. - Antihypertensive agents: potential additive blood‑pressure effects. - Immunosuppressants (e.g., azathioprine): heightened infection risk.